DiaMedica reports FY2022 cash $33.5M, updates on ReMEDy2 clinical hold progress

DiaMedica Therapeutics Inc.

Cash and investments of $33.5M at Dec 31, 2022 vs $45.1M at end of 2021; cash runway into Q4 2024.
R&D expenses fell to $7.8M in 2022 from $8.8M; G&A expenses rose to $6.2M from $4.9M.
FDA clinical hold on ReMEDy2 remains; Part 1 in-use study completed, supports dose revision to avoid hypotension; Part 2 data due April 2023.
Phase 1C SAD study of DM199 started in Australia to confirm IV dose; enrollment underway, preliminary data expected May 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DiaMedica Therapeutics Inc. reported financial results for for the year ended December 31, 2022.

Period: for the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 28, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-008188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.